Bioanalytical
Clavulanate and Meropenem combination effective in dealing with TB
Mar 30 2012
Biochemistry researchers have combined clavulanate and the antibiotic meropenem, finding that the pair offer an effective treatment for tuberculosis (TB).
John Blanchard, Ph.D., professor of Biochemistry at the Albert Einstein School of Medicine of Yeshiva University in New York City, said: "We've tested this combination against laboratory strains of Mtb, XDR and MDR strains from patients. In all cases, the combination doesn't just slows down growth — it kills the bacterium in laboratory tests."
The bacterium in TB has started to develop resistances to current medication, which consists of isoniazid, pyrazinamide, rifampin, and ethambutol. Some strains of TB are resistant to more drugs, which makes this an increasingly pressing issue to deal with, for example, a physician in India reported a strain of TB that it 100 per cent drug resistant.
Combining clavulanate and meropenem kills MDR and XDR strains of Mtb, which contains beta-lactamase. This is what has been killing off antibiotics, and rendering many other drugs ineffective. The new study proved that clavulanate would stop the enzyme in TB microbes from attacking and destroying antibiotics.
Posted by Ben Evans
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jan 20 2025 Amsterdam, Netherlands
Feb 03 2025 Dubai, UAE
Feb 05 2025 Guangzhou, China
Mar 01 2025 Boston, MA, USA
Mar 04 2025 Berlin, Germany